PCA
GSK icon

Providence Capital Advisors’s GSK GSK Stock Holding History

Providence Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed – – 329
2022
Q2 		$0 Hold
3
– – ﹤0.01% 360
2022
Q1 		$0 Hold
3
– – ﹤0.01% 482
2021
Q4 		$0 Hold
3
– – ﹤0.01% 348
2021
Q3 		$0 Hold
3
– – ﹤0.01% 320
2021
Q2 		$0 Sell
3
-4
-57% -$192 ﹤0.01% 323
2021
Q1 		$0 Sell
7
-36,323
-100% -$1.65M ﹤0.01% 302
2020
Q4 		$1.67M Buy
36,330
+4,563
+14% +$210K 0.68% 50
2020
Q3 		$1.5M Buy
31,767
+1,081
+4% +$54.2K 0.79% 48
2020
Q2 		$1.56M Sell
30,686
-320
-1% -$16.4K 0.89% 47
2020
Q1 		$1.47M Buy
31,006
+1,264
+4% +$67.4K 0.88% 52
2019
Q4 		$1.75M Buy
29,742
+484
+2% +$26.9K 0.94% 47
2019
Q3 		$1.56M Buy
29,258
+287
+1% +$14.8K 0.92% 53
2019
Q2 		$1.45M Buy
28,971
+9,993
+53% +$501K 0.86% 54
2019
Q1 		$991K Buy
18,978
+547
+3% +$27.3K 0.62% 70
2018
Q4 		$880K Buy
18,431
+630
+4% +$31K 0.6% 71
2018
Q3 		$894K Buy
17,801
+247
+1% +$12.5K 0.58% 72
2018
Q2 		$885K Buy
17,554
+361
+2% +$18.2K 0.62% 72
2018
Q1 		$840K Buy
17,193
+1,274
+8% +$59.3K 0.63% 72
2017
Q4 		$706K Buy
+15,919
New +$735K 0.55% 68

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Providence Capital Advisors's GSK Position: Q3 2022 in Review

Providence Capital Advisors sold out of GSK (GSK) in Q3 2022, closing a stake of 3 shares.

Providence Capital Advisors first reported a position in GSK in Q4 2017 and held it in 19 quarters. The position peaked at $1.75M in Q4 2019. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Providence Capital Advisors reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 3 GSK shares in Q3 2022.
  • Providence Capital Advisors first reported a position in GSK in Q4 2017 and held it in 19 quarters.
  • Providence Capital Advisors's GSK position peaked at $1.75M in Q4 2019.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Providence Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.